| Press Release Sumatriptan Injection |
|
| Press Release Dasatinib Tablets |
|
| Conversion into WhollyOwned Subsidiary Alembic Pharmaceuticals Scientific Office L.L.C., 6th November, 2025 |
|
| Related Party Transaction for the quarter ended 30th September, 2025 |
|
| Intimation Under Regulation 30 Newspaper Publication Of The Financial Results For The Quarter Ended 30th September, 2025 |
|
| Press Release Ticagrelor Tablets |
|
| Intimation of Investor Meet, 4th November, 2025 |
|
| Press Release Triamcinolone Acetonide Injectable Suspension |
|
| Intimaiton of BM, 4th November, 2025 |
|
| Intimation Under Regulation 30 Newspaper Publication Of Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares |
|
| Intimation Under Regulation 30 Newspaper Publication Of Saksham Niveshak |
|
| Intimation for Change in Email Address of the RTA of the Company |
|
| Press Release for Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg |
|
| Intimation Under Regulation 30 Loss Of Share Certificate Dated 15th September, 2025 |
|
| Alembic Pharmaceuticals Limited receives EIR for API-I & API-II, Panelav |
|
| Press Release for Phytonadione Injectable Emulsion |
|
| Intimation of Investor Meet, 29th August, 2025 Signed |
|
| Press Release for Macitentan Tablets |
|
| Intimation of Investor Meet, 22nd August, 2025 |
|
| Intimation of Investor Meet, 18th August, 2025 |
|
| Press Release For Tretinoin Cream USP |
|
| Intimation under Regulation 30 Newspaper Publication of the Financial Results for the Quarter ended June, 2025 |
|
| Contact Details of Key Managerial Personnel Senior Officials |
|
| SE Intimation SMP, 31st July, 2025 |
|
| Press Release for Carbamazepine Extended-Release Tablets |
|
| Intimation of Credit Rating of Enhanced Amount of Bank Loans, CRISIL |
|
| Intimation of Investor Meet, 5th August, 2025 |
|
| Intimation of BM, 5th August, 2025 |
|
| SE Intimation SMP, 21st July, 2025 |
|
| SE Intimation SMP, 8th July 2025 |
|
| Intimation for Relinquishment of CFO of the Company |
|
| Intimation for Appointment of CFO of the Company |
|
| SE Intimation - Letter to Shareholders |
|
| Intimation of receipt of Demand Note dated 1st July, 2025 |
|
| Intimation under Regulation 30 - Loss of Share Certificate Dated 2nd July, 2025 |
|
| Response on Clarification on Volume Movement BSE |
|
| Press Release for Doxorubicin Hydrochloride Liposome Injection |
|
| SE Intimation SMP, 31st May, 2025 |
|
| Alembic Pharmaceuticals Limited receives EIR for its API-III Facility at Karakhadi |
|
| Intimation of Investor Meet 25th June, 2025 |
|
| Corporate Guarantee issued on 17th June, 2025 |
|
| Intimation for Credit Rating of Enhanced Amount of CP, CRISIL |
|
| Intimation for Credit Rating of Enhanced Amount of CP, CARE |
|
| USFDA Inspection at API -I & II Facility Panelav, 31st May 2025 |
|
| Press Release for Final Approval of Bosutinib Tablets 100 mg and 500 mg |
|
| Intimation of Update in Investor Meet |
|
| Press Release for Final Approval of Amlodipine and Atorvastatin Tablets |
|
| Intimation of Investor Meet, 28th May, 2025 |
|
| Intimation of Investor Meet, 23rd May, 2025 |
|
| Intimation under Regulation 30 Unclaimed Shares Dated 15th May, 2025 |
|
| Intimation under Regulation 30 Loss of Share Certificate Dated 15th May, 2025 |
|
| SE Intimation SMP, 15th May, 2025 |
|
| Press Release for final approval of Rivaroxaban Tablets 2.5 mg, 10 mg, 15 mg, and 20 mg |
|
| Intimation Newspaper Publication Financial Results 7th May, 2025 |
|
| Intimation Newspaper Publication, 7th May, 2025 |
|
| Intimation - Appointment of Secretarial Auditors and Change in Statutory Auditors |
|
| Specimen Reminder Letter to Shareholders IEPF |
|
| Press Release for Final Approval for Ticagrelor Tablets, 90 mg and Tentative Approval for Ticagrelor Tablets, 60 mg |
|
| Alembic Pharmaceuticals Limited receives EIR for its F-2 Formulation Facility, Panelav |
|
| Commissioning of Pithampur Plant 26th April, 2025 |
|
| Intimation of Investor Meet, 6th May, 2025 |
|
| Intimation of BM 6th May, 2025 |
|
| Intimation for Change in Email Address and Website Address of RTA of the Company |
|
| Press Release FA for Carbamazepine Tablets USP, 200 mg |
|
| Intimation under Regulation 30 Dated 3rd April, 2025 |
|
| Press Release FA for Pantoprazole Sodium injection 40 mgvial (Single Dose Vial) |
|